BASDAI, ASAS and ASDAS response rates in patients with ankylosing spondylitis (AS) compared with patients with non-radiographic axial spondyloarthritis (nr-axSpA) after 1 year of treatment with etanercept
| Parameter at week 48 | ETA, AS, (n=20) | ETA, nr-axSpA (n=20) |
|---|---|---|
| BASDAI20, % (95% CI) | 80 (59 to 93) | 85 (65 to 96) |
| BASDAI50, % (95% CI) | 55 (34 to 75) | 75 (54 to 90) |
| ASAS40, % (95% CI) | 75 (54 to 90) | 65 (43 to 83) |
| ASAS partial remission, % (95% CI) | 40 (21 to 62) | 60 (38 to 79) |
| ASDAS clinically important improvement, %* | 55 (34 to 75) | 75 (54 to 90) |
| ASDAS major improvement, %† | 30 (14 to 52) | 25 (10 to 46) |
| ASDAS inactive disease (<1.3), % (95% CI) | 40 (21 to 62) | 40 (21 to 62) |
Results shown as percentage (%) and 95% CI. No statistical differences between patients with AS versus nr-axSpA were found for any of the parameters (p>0.05).
*ASDAS clinically important improvement: change of ASDAS between baseline and follow-up ≥1.1.
†ASAS major improvement: change of ASDAS between baseline and follow-up ≥2.0.
AS, ankylosing spondylitis; ASDAS, Ankylosing Spondylitis Disease Activity Score; ASAS40/partial remission, response of the Assessment of SpondyloArthritis international society (ASAS) criteria for 40% improvement in disease activity; ASAS criteria for partial remission; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASDAI20/50, Bath Ankylosing Spondylitis Disease Activity Index criteria for 20% and 50% improvement at week 48; CRP, C-reactive protein; ETA, etanercept; n, number of patients; nr-axSpA, nonradiographic axial spondyloarthritis.